SCHEMBL479494

SCHEMBL479494

CNc1ccc(C#N)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HCAR3 P49019 1/20 0.44
NNMT P40261 1/20 0.43
TMPRSS4 Q9NRS4 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
TRPV4 Q9HBA0 1/20 0.42
CCNK O75909 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK12 Q9NYV4 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
CCR6 P51684 1/20 0.40
IDH1 O75874 1/20 0.40
DEGS1 O15121 1/20 0.39
ABCB1 P08183 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30401857 1.00 KDM4E (0.46) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL8989496 0.81 TMPRSS4 (0.47) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL1344704 0.80 KDM4E (0.43) KDM4EALDH1A1L3MBTL1MEN1KMT2A
Water SCHEMBL6221139 0.79 KDM4E (0.57) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL247841 0.79 KDM4E (0.57) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL24991566 0.79 MEN1 (0.45) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL503729 0.79 HCAR3 (0.44) MEN1KMT2AHCAR3NNMTMTOR
SCHEMBL29624542 0.79 KDM4E (0.57) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3060340 0.79 HCAR3 (0.49) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2815504 0.79 HCAR3 (0.49) KDM4EALDH1A1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258355-B2 Probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2025-03-25 US disclosed
WO-2025021943-A1 QUINAZOLINONE, BENZOXAZINONE AND BENZOXAZEPINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS NEURALIS (BE) 2025-01-30 WO disclosed
WO-2024127363-A1 TYK2 PSEUDOKINASE LIGANDS AND USES THEREOF ALEMBIC PHARMACEUTICALS LIMITED (IN) 2024-06-20 WO disclosed
WO-2024029489-A1 KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF MODULUS DISCOVERY, INC. (JP) 2024-02-08 WO disclosed
EP-3676252-B1 DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE CHULABHORN FOUND (TH) 2023-11-29 EP disclosed
CN-112204006-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2023-11-28 CN disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
CN-116655618-A Probes for imaging huntingtin CHDI基金会股份有限公司 2023-08-29 CN disclosed
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2023-07-06 US disclosed
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2023-07-06 US disclosed
US-20060089365-A1 Heterocyclic compounds useful as nurr-1 activators NOVARTIS AG (CH) 2006-04-27 US disclosed
EP-1597243-A1 HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS Novartis AG (CH) 2005-11-23 EP disclosed
WO-2005075426-A1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF GLENMARK PHARMACEUTICALS LTD. (US) 2005-08-18 WO disclosed
WO-2004072050-A1 HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS NOVARTIS AG (CH) 2004-08-26 WO disclosed
US-6462047-B1 CONTAINING 5- OR 6-MEMBERED OXYGEN, NITROGEN AND/OR SULFUR HETEROARYL GROUP; ANGINA, HYPERTENSION, RESPIRATORY DISTRESS, CONGESTIVE HEART FAILURE, RENAL FAILURE, ATHEROSCLEROSIS, INFLAMMATORY DISEASES, STROKES, BRONCHITIS, ASTHMA ICOS CORPORATION 2002-10-08 US disclosed
EP-1114048-A1 CARBOLINE DERIVATIVES AS CGMP PHOSPHODIESTERASE INHIBITORS Bombrun, Agnès (FR) 2001-07-11 EP disclosed
WO-2000015639-A1 CARBOLINE DERIVATIVES AS CGMP PHOSPHODIESTERASE INHIBITORS ICOS CORPORATION (US) 2000-03-23 WO disclosed
EP-0607803-B1 Process for the preparation of 6-amino-3-pyridinecarbonitriles BAYER AG (DE) 1996-07-10 EP disclosed
US-5480995-A Process for the preparation of 6-amino-nicotinonitriles BAYER AKTIENGESELLSCHAFT (DE) 1996-01-02 US disclosed
EP-0607803-A1 Process for the preparation of 6-amino-3-pyridinecarbonitriles BAYER AG (DE) 1994-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HSPBP1 KDM4E 4585/4885ALDH1A1 3976/4885L3MBTL1 3337/4885
US-20060089365-A1 Heterocyclic compounds useful as nurr-1 activators NCOR1, NCOR2, NR4A1 KDM4E 1429/4885ALDH1A1 1564/4885L3MBTL1 2456/4885
US-12258355-B2 Probes for imaging huntingtin protein HTT, HYPK, HSPBP1 KDM4E 4585/4885ALDH1A1 3976/4885L3MBTL1 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.